P085 Rethinking migraine: will shifting the emphasis towards preventative treatment of migraine, using new CGRP-targeting medicines, be of added value to society from a health economics perspective?

Tinelli, M. ORCID: 0000-0002-8816-4389 and Quoidbach, V. (2024) P085 Rethinking migraine: will shifting the emphasis towards preventative treatment of migraine, using new CGRP-targeting medicines, be of added value to society from a health economics perspective? Journal of Headache and Pain, 25 (S1). ISSN 1129-2377

Text (s10194-024-01793-4) - Published Version Available under License Creative Commons Attribution. Download (25MB)

• https://www.webofscience.com/api/gateway...
• https://thejournalofheadacheandpain.biom...

Abstract

Objective: The calcitonin gene-related peptide [CGRP] receptor antagonists are new therapies with demonstrated efficacy both in treatment and prevention of migraine attacks. Their place among the range of treatments needs to be established. CGRP-targeting medicines include gepants (small molecular antagonists) and anti-CGRP antibodies. Our objective is to assess the evidence of cost-effectiveness of CGRP-targeting medicines in migraine prevention (alone or in combination with other approaches) as a prerequisite for evaluating the marginal cost-effectiveness of introducing these CGRP-targeting medicines into the range of preventative measures, both pharmacological and non-pharmacological. Methods: We will first conduct scoping literature reviews of (a) cost-of-illness of episodic (EM) and chronic (CM) migraine and (b) cost-effectiveness of preventative treatments for EM and CM, with particular focus on CGRP-targeting medicines. Subsequently we will conduct decision analytic modelling. Results: Preliminary results from the literature reviews and our plans for the economic modelling will be presented. Conclusion: In clinical trials, not all patients have benefited from the preventative effects of CGRP-targeting medicines. At the same time, these newly-developed drugs are relatively costly. In these circumstances, the public-health benefits of introducing them are uncertain. These and further studies are needed to understand whether, and by how much, CGRP-targeting medicines, when optimally introduced among other therapeutic options, will improve outcomes at what increase in costs.

Item Type:	Article
Additional Information:	© 2024 The Author(s)
Divisions:	Care Policy and Evaluation Centre
Subjects:	R Medicine > RC Internal medicine
Date Deposited:	03 Oct 2024 15:30
Last Modified:	12 Dec 2024 04:30
URI:	http://eprints.lse.ac.uk/id/eprint/125614

Actions (login required)

View Item